Teleflex Reports First Quarter 2015 Results and Reaffirms 2015 Guidance

April 30, 2015

First Quarter Revenues of $429.4 million, down 2.1% over prior year period; up 5.2% on Constant Currency Basis

First Quarter GAAP Diluted EPS of $0.83, up 7.8% over the prior year period

First Quarter Adjusted Diluted EPS of $1.30, up 6.6% over the prior year period

2015 Constant Currency Revenue and Adjusted Diluted EPS Guidance Reaffirmed

WAYNE, Pa.--(BUSINESS WIRE)--Apr. 30, 2015-- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 29, 2015.

First quarter net revenues were $429.4 million, a decrease of 2.1% over the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 5.2% over the year ago quarter.

First quarter GAAP diluted earnings per share from continuing operations increased 7.8% to $0.83, as compared to $0.77 in the prior year period. First quarter adjusted diluted earnings per share from continuing operations increased 6.6% to $1.30, compared to $1.22 in the prior year period.

“2015 is off to a good start from an operating perspective and slightly ahead of our initial expectations,” said Benson Smith, Chairman, President and Chief Executive Officer. “We generated solid, mid-single digit constant currency revenue growth, and continued to expand gross and operating margins. In addition, during the first quarter, the Company achieved a significant milestone in our strategy of advancing minimally invasive surgery with the first laparoscopic procedure using Teleflex’s Percuvance™ Percutaneous Surgical System in a large U.S. hospital system. Based on our first quarter results, Teleflex remains on target to achieve our previously provided constant currency revenue growth and adjusted diluted earnings per share guidance for 2015.”

FIRST QUARTER NET REVENUE BY SEGMENT AND GEOGRAPHY

Vascular North America first quarter net revenues were $67.9 million, an increase of 8.7% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 9.2% compared to the year ago quarter. The increase in constant currency revenue was largely due to higher sales volume of existing products.

Surgical North America first quarter net revenues were $38.1 million, an increase of 8.0% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 9.4% compared to the year ago quarter. The increase in constant currency revenue was largely due to price increases, new product sales, MiniLap product sales and higher sales volume of existing products.

Anesthesia/Respiratory North America first quarter net revenues were $55.4 million, an increase of 1.2% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 1.6% compared to the year ago quarter. The increase in constant currency revenue was largely due to new product sales.

EMEA first quarter net revenues were $129.3 million, a decrease of 14.0% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 2.2% compared to the year ago quarter. The increase in constant currency revenue was largely due to higher sales volume of existing products and new product sales.

Asia first quarter net revenues were $48.5 million, a decrease of 2.2% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 7.0% compared to the year ago quarter. The increase in constant currency revenue was largely due to product sales resulting from the acquisitions of Mayo Healthcare Pty Ltd. and Human Medics Co. Ltd., price increases and new product sales, somewhat offset by lower sales volume of existing products.

OEM and Development Services (“OEM”) first quarter net revenues were $34.7 million, an increase of 4.6% compared to the first quarter 2014. Excluding the impact of foreign currency fluctuations, first quarter net revenues increased 8.2% compared to the year ago quarter. The increase in constant currency revenue was largely due to higher sales volume of existing products and new product sales.

                   
Three Months Ended % Increase/ (Decrease)
March 29, 2015 March 30, 2014

Constant

Currency

Foreign

Currency

Total

Change

(Dollars in millions)
Vascular North America $ 67.9 $ 62.5 9.2 % (0.5 %) 8.7 %
Surgical North America 38.1 35.2 9.4 % (1.4 %) 8.0 %
Anesthesia/Respiratory North America 55.4 54.7 1.6 % (0.4 %) 1.2 %
EMEA 129.3 150.2 2.2 % (16.2 %) (14.0 %)
Asia 48.5 49.6 7.0 % (9.2 %) (2.2 %)
OEM 34.7 33.2 8.2 % (3.6 %) 4.6 %
All Other   55.5   53.1 6.0 % (1.3 %) 4.7 %
Total $ 429.4 $ 438.5 5.2 % (7.3 %) (2.1 %)
 

OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS

Depreciation expense, amortization of intangible assets and deferred financing costs for the first three months of 2015 aggregated $29.9 million compared to $31.4 million for the prior year period.

Cash and cash equivalents at March 29, 2015 were $308.8 million compared to $303.2 million at December 31, 2014.

Net accounts receivable at March 29, 2015 were $284.8 million compared to $273.7 million at December 31, 2014.

Net inventories at March 29, 2015 were $338.7 million compared to $335.6 million at December 31, 2014.

Net debt obligations at March 29, 2015 were $825.8 million compared to $801.4 million at December 31, 2014.

2015 OUTLOOK

The Company reaffirmed its full year 2015 financial estimates as follows:

The Company continues to estimate that constant currency revenue growth will be between 4% and 6%. On a GAAP basis, revenues are expected to be flat to down 2% versus the prior year due to the unfavorable impact of foreign currency fluctuations.

The Company also continues to estimate that adjusted diluted earnings per share from continuing operations will be between $6.10 and $6.35, representing an increase of 6.3% to 10.6% over the prior year. Previously, the Company expected foreign currency fluctuations to negatively impact adjusted earnings per share in 2015 by approximately 14%. Our current expectation reflects that foreign currency fluctuations will negatively impact adjusted earnings per share in 2015 by approximately 15%. The Company has updated its full year 2015 GAAP diluted earnings per share from continuing operations range from $4.22 to $4.37 to a range of $4.13 to $4.28.

       

FORECASTED 2015 CONSTANT CURRENCY REVENUE GROWTH RECONCILIATION

 
Low     High
 
Forecasted 2015 GAAP revenue growth (2%)
 
Estimated impact of foreign currency fluctuations 6%     6%
 
Forecasted 2015 constant currency revenue growth 4%     6%
 
 

FORECASTED 2015 ADJUSTED EARNINGS PER SHARE RECONCILIATION

 
Low     High
 
Diluted earnings per share attributable to common shareholders $4.13 $4.28
 
Restructuring, impairment charges and special items, net of tax $0.90 $0.95
 
Intangible amortization expense, net of tax $0.90 $0.95
 
Amortization of debt discount on convertible notes, net of tax $0.17     $0.17
 
Adjusted diluted earnings per share $6.10     $6.35
 

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until May 7, 2015 at 11:59pm (ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 72082025.

ADDITIONAL NOTES

Constant currency revenue growth excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

This press release includes certain non-GAAP financial measures, which include:

Adjusted diluted earnings per share. This measure excludes, depending on the period presented (i) the effect of charges associated with our restructuring programs; (ii) losses and other charges, including acquisition and integration costs, charges related to facility consolidations, and charges related to contingent consideration liabilities, net of specified reversals, including a reversal of liabilities related to certain contingent consideration arrangements during the quarter ended March 31, 2014; (iii) amortization of the debt discount on the Company’s convertible notes; (iv) intangible amortization expense; and (v) tax benefits resulting from the resolution of, or expiration of the statute of limitations with respect to, prior years’ tax matters. In addition, the calculation of diluted shares within adjusted earnings per share gives effect to the anti-dilutive impact of the Company’s convertible note hedge agreements, which reduce the potential economic dilution that otherwise would occur upon conversion of the Company’s senior subordinated convertible notes (under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares).

Constant currency revenue growth. This measure excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period.

Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. In addition, management believes that the calculation of non-GAAP diluted shares is useful to investors because it provides insight into the offsetting economic effect of the convertible note hedge against conversions of the convertible notes. Management uses these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with generally accepted accounting principles (“GAAP”) and should not be relied upon as a substitute for GAAP financial measures. Tables reconciling historical adjusted diluted earnings per share to historical GAAP earnings per share are set forth below. Tables reconciling constant currency net revenues to GAAP net revenues and reconciling forecasted non-GAAP measures to the most directly comparable forecasted GAAP measures are set forth above.

 
RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS
Dollars in millions, except per share amounts
 
 
Quarter Ended – March 29, 2015
   

Cost

of

goods sold

   

Selling,

general and

administrative

expenses

   

Restructuring

and other

impairment

charges

   

Interest

expense, net

   

Income

taxes

   

Net income

(loss)

attributable to

common

shareholders

from continuing

operations

   

Diluted earnings

per share

available to

common

shareholders

   

Shares used in

calculation of

GAAP and

adjusted

earnings per

share

 
GAAP Basis $206.8 $139.7 $4.4 $17.0 $9.3 $39.1 $0.83 47,295
Adjustments

Restructuring and other impairment charges

4.4 1.6 2.8 $0.06

Losses and other charges (A)

2.1 0.9 0.8 2.2 $0.05

Amortization of debt discount on convertible notes

3.2 1.2 2.0 $0.04
Intangible amortization expense 14.7 3.8 11.0 $0.23
Tax adjustment (B) (0.2) 0.2

Shares due to Teleflex under note hedge (C)

$0.09 (3,056)
Adjusted basis $204.7 $124.0 $13.8 $16.5 $57.3 $1.30 44,239
 
 
Quarter Ended – March 30, 2014

Cost

of

goods sold

Selling,

general and

administrative

expenses

Restructuring

and other

impairment

charges

Interest

expense, net

Income

taxes

Net income

(loss)

attributable to

common

shareholders

from continuing

operations

Diluted earnings

per share

available to

common

shareholders

Shares used in

calculation of

GAAP and

adjusted

earnings per

share

 
GAAP Basis $217.4 $140.3 $7.8 $15.2 $8.5 $35.1 $0.77 45,749
Adjustments

Restructuring and other impairment charges

7.8 1.1 6.7 $0.15
Losses and other charges (A) (0.1) 0.8 (0.9) ($0.02)

Amortization of debt discount on convertible notes

3.0 1.1 1.9 $0.04
Intangible amortization expense 16.0 5.5 10.5 $0.23

Tax adjustment (B)

0.2 (0.2)

Shares due to Teleflex under note hedge (C)

$0.06 (2,450)
Adjusted basis $217.4 $124.4 $12.2 $17.2 $53.0 $1.22 43,299
 

(A) In 2015, losses and other charges include approximately $1.9 million, net of tax, or $0.04 per share, related to acquisition and integration costs, and charges related to facility consolidations; and approximately $0.3 million, net of tax, or $0.01 per share, related to contingent consideration liabilities. In 2014, losses and other charges include approximately $1.4 million, net of tax, or $0.03 per share, related to acquisition and integration costs; reversals included approximately $2.3 million, net of tax, or ($0.05) per share, related to the reversal of contingent consideration liabilities.

(B) The tax adjustment represents a net benefit resulting from the resolution of, or the expiration of statute of limitations with respect to various prior years’ U.S. federal, state and foreign tax matters.

(C) Adjusted diluted shares are calculated by giving effect to the anti-dilutive impact of the Company’s convertible note hedge agreements, which reduce the potential economic dilution that otherwise would occur upon conversion of our senior subordinated convertible notes. Under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares.

 

RECONCILIATION OF NET DEBT OBLIGATIONS

 
    March 29, 2015     December 31, 2014
(Dollars in thousands)
 
Note payable and current portion of long term borrowings $ 401,565 $ 368,401
 
Long term borrowings 700,000 700,000
 
Unamortized debt discount   32,981   36,197
 
Total debt obligations 1,134,546 1,104,598
 
Less: cash and cash equivalents   308,759   303,236
 
Net debt obligations $ 825,787 $ 801,362
 

ABOUT TELEFLEX INCORPORATED

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 12,200 people and serves healthcare providers worldwide. For additional information about Teleflex please refer to www.teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, forecasted 2015 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance and unanticipated difficulties in connection with the introduction of new products and product line extensions; product recalls; unanticipated difficulties in connection with the consolidation of manufacturing and administrative functions, including as a result of difficulties with various employees, labor representatives or regulators; the loss of skilled employees in connection with such initiatives; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses; the impact of government healthcare reform legislation; our ability to meet our debt obligations; changes in general and international economic conditions including fluctuations in foreign currency exchange rates; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2014.

 

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 
 
    Three Months Ended
March 29,

2015

    March 30,

2014

(Dollars and shares in thousands,

except per share)

 
Net revenues $ 429,430 $ 438,546
Cost of goods sold   206,793     217,387  
Gross profit 222,637 221,159
Selling, general and administrative expenses 139,697 140,297
Research and development expenses 12,884 14,062
Restructuring and other impairment charges   4,448     7,780  
Income from continuing operations before interest and taxes 65,608 59,020
Interest expense 17,172 15,404
Interest income   (169 )   (187 )
Income from continuing operations before taxes 48,605 43,803
Taxes on income from continuing operations   9,332     8,534  
Income from continuing operations   39,273     35,269  
Operating loss from discontinued operations (499 ) (25 )
Taxes on loss from discontinued operations   204     100  
Loss from discontinued operations   (703 )   (125 )
Net income 38,570 35,144
Less: Income from continuing operations attributable to noncontrolling interest   218     186  
Net income attributable to common shareholders $ 38,352   $ 34,958  
 
Earnings per share available to common shareholders:
Basic:
Income from continuing operations $ 0.94 $ 0.85
Loss from discontinued operations   (0.02 )    
Net income $ 0.92   $ 0.85  
 
Diluted:
Income from continuing operations $ 0.83 $ 0.77
Loss from discontinued operations   (0.02 )   (0.01 )
Net income $ 0.81   $ 0.76  
 
Dividends per share $

0.34

$ 0.34
 
Weighted average common shares outstanding:
Basic 41,469 41,262
Diluted 47,295 45,749
 
Amounts attributable to common shareholders:
Income from continuing operations, net of tax $ 39,055 $ 35,083
Loss from discontinued operations, net of tax   (703 )   (125 )
Net income $ 38,352   $ 34,958  
 
 

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 
 
    March 29,

2015

   

December 31,

2014

 
(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents $ 308,759 $ 303,236
Accounts receivable, net 284,827 273,704
Inventories, net 338,736 335,593
Prepaid expenses and other current assets 40,935 35,697
Prepaid taxes 33,993 40,256
Deferred tax assets 56,562 57,301
Assets held for sale   6,959   7,422
Total current assets 1,070,771 1,053,209
Property, plant and equipment, net 310,106 317,435
Goodwill 1,293,506 1,323,553
Intangible assets, net 1,183,549 1,216,720
Investments in affiliates 734 1,150
Deferred tax assets 1,119 1,178
Other assets   63,810   64,010

Total assets

$ 3,923,595 $ 3,977,255
 
LIABILITIES AND EQUITY
Current liabilities
Current borrowings $ 401,565 $ 368,401
Accounts payable 75,310 64,100
Accrued expenses 71,905 72,383
Current portion of contingent consideration 7,462 11,276
Payroll and benefit-related liabilities 66,324 85,442
Accrued interest 12,855 9,169
Income taxes payable 17,558 13,768
Other current liabilities   11,446   10,360

Total current liabilities

664,425 634,899
Long-term borrowings 700,000 700,000
Deferred tax liabilities 426,768 451,541
Pension and postretirement benefit liabilities 162,595 167,241
Noncurrent liability for uncertain tax positions 49,334 50,884
Other liabilities   59,871   58,991
Total liabilities 2,062,993 2,063,556
Commitments and contingencies
Total common shareholders’ equity 1,857,933 1,911,309
Noncontrolling interest   2,669   2,390
Total equity   1,860,602   1,913,699
Total liabilities and equity $ 3,923,595 $ 3,977,255
 
       

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 
 
Three Months Ended
March 29, 2015 March 30, 2014
(Dollars in thousands)
Cash Flows from Operating Activities of Continuing Operations:
Net income $ 38,570 $ 35,144
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations 703 125
Depreciation expense 10,915 11,580
Amortization expense of intangible assets 14,740 16,019
Amortization expense of deferred financing costs and debt discount 4,195 3,814
Changes in contingent consideration 382 (2,371 )
Stock-based compensation 3,832 3,074
Deferred income taxes, net 1,085 3,515
Other (4,294 ) (3,105 )

Changes in operating assets and liabilities, net of effects of acquisitions and disposals:

Accounts receivable (21,906 ) 5,966
Inventories (14,578 ) (7,473 )
Prepaid expenses and other current assets (4,756 ) (6,027 )
Accounts payable and accrued expenses 3,819 (16,129 )
Income taxes receivable and payable, net   9,651     (2,214 )
Net cash provided by operating activities from continuing operations   42,358     41,918  
 
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment (14,445 ) (12,109 )
Proceeds from sale of assets and investments 1,669
Payments for businesses and intangibles acquired, net of cash acquired (7,375 ) (28,991 )
Investment in affiliates       (60 )
Net cash used in investing activities from continuing operations   (21,820 )   (39,491 )
 
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings 30,000
Repayment of long-term borrowings (52 )
Debt extinguishment, issuance and amendment fees (90 )
Net proceeds from share based compensation plans and the related tax impacts (289 ) 323
Payments for contingent consideration (3,989 )
Dividends   (14,118 )   (14,051 )
Net cash provided by (used in) financing activities from continuing operations   11,552     (13,818 )
 
Cash Flows from Discontinued Operations:
Net cash used in operating activities   (1,126 )   (1,167 )
Net cash used in discontinued operations   (1,126 )   (1,167 )
 
Effect of exchange rate changes on cash and cash equivalents   (25,441 )   2,223  
Net decrease in cash and cash equivalents 5,523 (10,335 )
Cash and cash equivalents at the beginning of the period   303,236     431,984  
Cash and cash equivalents at the end of the period $ 308,759   $ 421,649  
 

Source: Teleflex Incorporated

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President of Investor Relations
610-948-2836